

## **ERT Facilitates Global Growth with Appointment of Klaus Besier to Board of Directors**

RealWire

*Industry Expert Brings Significant Record of Executive Leadership in Sales, Marketing and Global Business Development to Growing Company*

**PHILADELPHIA, PA 14 December 2010** ERT, a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Klaus Besier to the Company's Board of Directors. This strategic appointment will enable ERT to draw on Mr. Besier's extensive experience and international perspective in helping companies develop, implement and execute global growth strategies to further penetrate health care and clinical markets.



**Klaus Besier**

Mr. Besier brings to ERT more than 30 years of executive experience in leading software technology companies. He has served as President and CEO of SAP America, Inc. and is credited with driving its growth in North and South America, Australia and New Zealand from \$50 million to \$1 billion in revenues in less than five years. In addition, as President and CEO of Firepond Inc., Mr. Besier took the company public in one of the most successful IPOs of 2000.

Mr. Besier also held the position of President and CEO of Neoware, Inc., where he drove significant changes in the company's go-to-market and partner strategies. The improved corporate structure led to significant growth and visibility for the organization, resulting in its acquisition by HP in 2007 with a total transaction value of more than \$300 million. Most recently, Mr. Besier served as CEO of Pramata, Inc., where he refined a go-to-market strategy that is steering the company toward

growth with Fortune 500 customers. Today, he is the CEO of RES Software and a member of the Board of Directors of ICG Commerce.

Joel Morganroth, Chairman and Chief Scientific Officer of ERT, comments, "ERT strives to continually improve in all areas of business and grow into adjacent and complementary markets, ensuring our pledge to our customers of 'getting it done right.' With his wealth of experience and capabilities in developing and implementing successful growth strategies, we are confident that Klaus will greatly contribute to the strategic direction of the business and help ERT achieve its many goals."

Klaus Besier adds, "As the industry leader in cardiac safety, respiratory and multi-mode ePRO solutions for the clinical trial market, ERT has provided unparalleled scientific and regulatory leadership to the global health care industry. I am delighted to be part of a strong management team consisting of individuals who share a long industry track record. I look forward to working with them to take ERT to an even higher level of leadership and technological innovation."

For further information on ERT and its technology and services, please email [info@ert.com](mailto:info@ert.com) [1], call +1 215 972 0420 or visit [www.ert.com](http://www.ert.com) [2].

For further press information, please contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, email [ert@scottpr.com](mailto:ert@scottpr.com) [3].

## **About ERT**

Based in Philadelphia, PA, eResearchTechnology, Inc. ([www.ert.com](http://www.ert.com) [2]) is a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries. The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. It is also a leading provider of centralized respiratory technology and services to evaluate pulmonary function efficacy and safety in clinical development. Sponsors can further use the Company's solutions to streamline the clinical trials process by automating the collection, analysis, and distribution of ePRO clinical data using multi-mode technology in all phases of clinical development as well as selected medical devices for the clinical trials and healthcare industries.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

## Media Contacts:

Fiona Robinson  
The Scott Partnership  
Tel: +44 1477 539539  
[ert@scottpr.com](mailto:ert@scottpr.com) [3]

John Blakeley  
ERT  
+1 215 972 0420  
[jblakeley@ert.com](mailto:jblakeley@ert.com) [4]

[SOURCE](#) [5]

## Source URL (retrieved on 03/06/2015 - 4:25pm):

<http://www.mdtmag.com/news/2010/12/ert-facilitates-global-growth-appointment-klaus-besier-board-directors>

## Links:

- [1] <mailto://www.realwire.com/releases/info@ert.com>
- [2] <http://www.ert.com>
- [3] <mailto://www.realwire.com/releases/ert@scottpr.com>
- [4] <mailto://www.realwire.com/releases/jblakeley@ert.com>
- [5] <http://www.realwire.com/releases/ERT-Facilitates-Global-Growth-with-Appointment-of-Klaus-Besier-to-Board-of-Directors>